Inhibikase Therapeutics, Inc. SEC filings IKT

Inhibikase Therapeutics, Inc. has 368 filings in SEC EDGAR's recent list, going back to Aug 31, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 20, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
10-K Annual report Mar 26, 2026 Dec 31, 2025
ARS Annual report to shareholders May 12, 2025 Dec 31, 2024
10-K/A Amended annual report Apr 25, 2025 Dec 31, 2024
10-K Annual report Mar 27, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 26, 2024 Dec 31, 2023
10-K Annual report Mar 27, 2024 Dec 31, 2023
10-K/A Amended annual report Oct 16, 2023 Dec 31, 2022
ARS Annual report to shareholders May 5, 2023 Dec 31, 2022
10-K Annual report Mar 31, 2023 Dec 31, 2022
10-K Annual report Mar 31, 2022 Dec 31, 2021
10-K Annual report Mar 31, 2021 Dec 31, 2020

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IKT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Wilmington, DE
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1750149

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.